Posted on 3/18/2020
CryoLife, Inc., a company based outside of Atlanta, Georgia, announced this week that it has received the European CE Mark for the E-vita Open NEO, a hybrid stent graft system for the treatment of aortic arch disease.
Aortic arch disease encompasses both aortic aneurysms and aortic dissections, which occur suddenly and could be fatal. According to the release, about 7,000 patients are treated surgically for aortic arch disease annually in Europe, the Middle East, and Africa. Many patients with either an aneurysm or dissection in the aortic arch also present with a dissected or aneurys...